The application discloses application of
tamibarotene in preparation of a
medicine for preventing and / or treating
liver fibrosis, and belongs to the technical field of biological
medicine. The application finds that
tamibarotene has a significant anti-
liver fibrosis effect for the first time. Experimental results show that in two kinds of
liver fibrosis animal models induced by CCl4 and TAA,
tamibarotene can significantly down-regulate the expression of alpha-SMA and
type I collagen, reduce the liver
inflammatory response, and improve
liver function. In particular, the anti-
fibrosis effect of tamibarotene is significantly better than that of RARbeta selective
agonist KCL-286 and RARalpha selective
agonist Am580, and an unexpected technical effect is achieved. The application provides a new
medicine selection for the treatment of liver
fibrosis, and has a good clinical application prospect and development value.